Sunitinib-resistant KIT mutants do not bind sunitinib

Stable Identifier
R-HSA-9669878
Type
Reaction [transition]
Species
Homo sapiens
Compartment
plasma membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Sunitinib-resistant KIT mutants do not bind sunitinib
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Sunitinib is an approved therapeutic for the treatment of KIT mutant cancers. Sunitinib is effective against KIT primary mutations and against secondary mutations in the ATP-binding domain encoded by exon 13 and exon 14, but less effective against activation loop mutations encoded by exon 17 and 18, which show resistance to the drug (Nishida et al, 2009; Serrano et al, 2017; Serrano et al, 2019; Gajiwala et al, 2008; Garner et al, 2014; Roskoski, 2018)
Literature References
PubMed ID Title Journal Year
25239608 Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients

Anjum, R, Heinrich, MC, Ketzer, J, Bauer, S, Zhu, M, Zhou, T, Serrano, C, Song, Y, Fletcher, JA, Schrock, A, Ning, Y, Eilers, G, Wardwell, S, Gozgit, JM, Kohlmann, A, Garner, AP, Rivera, VM, Vodala, S, Clackson, T, Wang, F

Clin. Cancer Res. 2014
28478525 Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors

Morales-Barrera, R, Carles, J, Suárez, C, García-Valverde, A, Olivares, D, Valverde, C, George, S, Serrano, C

Target Oncol 2017
19390946 Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene

Doi, T, Nakajima, K, Nishida, T, Nishitani, A, Takahashi, T, Komatsu, Y, Japanese Study Group on Gist, -, Hirota, S, Shirao, K

Int. J. Clin. Oncol. 2009
29704617 The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders

Roskoski, R

Pharmacol. Res. 2018
19164557 KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

Quenzer, T, Emmett, MR, Deshmukh, GD, Lunney, EA, English, JM, Wu, JC, Christensen, J, Molina, D, He, YA, Zhang, Y, Greig, MJ, Demetri, GD, Yu, X, Diehl, W, McTigue, M, Gajiwala, KS, DiNitto, JP, Wells, PA, Jacques, SL, Zou, A, Zhang, HM, Marshall, AG

Proc. Natl. Acad. Sci. U.S.A. 2009
30792533 Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

Heinrich, MC, Ketzer, J, Bauer, S, Zhu, M, Presnell, A, Raut, CP, George, S, Mannan, AM, Serrano, C, Yu, C, Sicinska, E, Tao, DL, Rubin, BP, Fletcher, JA, Mariño-Enríquez, A, Demetri, GD, Eilers, G, Czaplinski, JT, McKinley, A

Br. J. Cancer 2019
Participants
Input
Participates
as an event of
Normal reaction
KIT binds type II TKIs (Homo sapiens)
Functional status

Loss of function of sunitinib resistant KIT mutants [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2020-04-01)
Reviewed
Pilco-Janeta, D  (2020-03-13)
Serrano, C  (2020-03-13)
García-Valverde, A  (2020-03-13)
Created
Rothfels, K  (2019-12-03)
Cite Us!